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Abstract
Background: Systemic sclerosis (SSc) is a rare and devastating disease affecting skin and internal organs. Familial
aggregation of SSc and co-aggregation with other autoimmune diseases is rarely reported.
Methods: We identified 23,658,577 beneficiaries registered with the National Health Insurance database in 2010,
1891 of whom had SSc. We identified 21,009,551 parent–child relationships and 17,168,340 full sibling pairs. The
familial risks of SSc and other autoimmune diseases and familial transmission were estimated.
Results: The prevalence of SSc in the general population was 0.008 %. There are 3801 individuals had at least one first-
degree relative with SSc, among them 3 people had SSc which was equivalent to a prevalence of 0.08 %. The adjusted
relative risk (RR) (95 % CI) for SSc was 81.21 (11.40–579.72) for siblings of SSc patients. The familial transmission (genetic
plus shared environmental contribution to total phenotypic variance of SSc) was 0.72. However, 84.1 % of patients
were expected to be sporadic cases. The RR (95 % CI) in first-degree relatives of SSc patients was 2.64 (1.46–4.75) for
rheumatoid arthritis, 6.51 (4.05–10.46) for systemic lupus erythematosus, 2.77 (1.04–7.35) for Sjögren’s syndrome, 8.05 (2.
03–31.92) for idiopathic inflammatory myositis, and 1.52 (1.15–2.01) for psoriasis.
Conclusions: The risks of SSc and other autoimmune diseases are increased in relatives of people with SSc, and family
factors explain over two-thirds of the phenotypic variance of the disease. These findings may be useful in counselling
families of patients with SSc and for further genetic studies.
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Background
Systemic sclerosis (SSc) is an uncommon autoimmune
disease characterized by the thickening of the skin and
involvement of internal organs including blood vessels,
heart, lung, kidney, and gastrointestinal tract. The preva-
lence and incidence of SSc are difficult to estimate be-
cause of its rarity and the difficulty to ascertain
diagnosis. In the United States, the prevalence has been
estimated at 24.2 cases per 100,000 adults [1]. In Taiwan,
our group recently estimated the prevalence of SSc to be
5.6 per 100,000 people using the National Health Insur-
ance (NHI) database, which contains health information
of almost all the inhabitants in Taiwan [2, 3]. The
outcome of SSc is generally thought to be poor, with a
higher mortality and an increased risk for other severe
comorbidity such as cancer [2–4].
SSc is thought to be a polygenic disorder which is con-
tributed to by both genetic and environmental factors
[5]. Evidence for familial aggregation has rarely been re-
ported but indicates a possible familial or genetic contri-
bution for SSc [6, 7]. The discovery of candidate genes
located in both major histocompatibility complex
(MHC) and non-MHC loci [8] has strengthened this
concept; however, the relative contribution of genetic
and shared environmental factors to SSc susceptibility
(familial transmission) has not been adequately esti-
mated. In addition, the precise estimates for familial
relative risks (RRs) for the disease and other associated
autoimmune diseases which are important parameters
for genetic counselling have not been reported despite
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evidence for familial aggregation of Raynaud’s syndrome
and an increased risk of SSc in individuals with a family
history of systemic lupus erythematosus (SLE) [9, 10]
and Sjögren’s syndrome [11].
Therefore, we conducted this nationwide study using
genealogy and linked health information derived from
the NHI database comprising essentially the entire
population of Taiwan in 2010 to determine familial ag-
gregation of SSc and to assess the relative contribution
of familial factors to susceptibility for the disease. In
addition, we also investigated the co-aggregation of
other autoimmune diseases with SSc.
Methods
Study population
This study was based on a cohort comprising all benefi-
ciaries of the Taiwan National Health Insurance (NHI)
system actively enrolled in 2010, which was constructed
using data from the registry for beneficiaries, registry for
catastrophic illness patients, and datasets of ambulatory
care expenditures and details of ambulatory case orders,
all of which are part of the NHI database. The enrol-
ment in the NHI system is mandatory by law for all citi-
zens and foreigners living longer than 6 months in
Taiwan and this is a single payer system managed by the
government. In 2010, over 99.5 % of the general popula-
tion in Taiwan was insured by the system [12]. The NHI
database is updated annually and records information on
personal details, socioeconomic status, family relation-
ships, dates of clinical visits, medical diagnoses, medical
expenditures, prescription details, examinations, and
procedures. All beneficiaries are given a unique identifi-
cation which allows precise internal linkage of all data
for a given individual. This identification was encrypted
before being released for research to ensure confidential-
ity but the uniqueness of the encrypted identification is
retained to ensure valid internal linkage.
Methods of identification of first-degree relatives and
family ascertainment have been reported previously [10,
11]. The relationships recorded in the NHI database in-
clude spouse, parent, offspring, and grandparents, grand-
children, great grandparent, and great grandchildren on
both paternal and maternal sides. The identification of sib-
lings was based on sharing one or more common parents.
In this study, half-siblings were excluded from the ana-
lysis. Twins were full siblings with the same date of birth
(±1 day) but twin zygosity cannot be derived from the
database. To consider the correlation among subjects
from the same family, we grouped individuals into families
according to their relationships. In total, 21,009,551 par-
ent–child relationships, 17,168,340 full sibling pairs and
342,066 twin pairs were identified and these relationships
were used to assemble 4,229,301 families with a mean
family size of five persons spanning up to five generations.
Case definition of SSc and other autoimmune diseases
The case definition for SSc was a person with a
catastrophic illness certificate for SSc (International
Classification of Diseases, Ninth Revision (ICD-9) code
7101). The holders of a catastrophic illness certificate
are entitled to a waiver of medical co-payments, which
must be supported by comprehensive clinical and la-
boratory assessment. Relevant information is sent to the
insurance administration for a formal review to confirm
the diagnosis before approval of waivers. The panel re-
views the diagnosis in compliance with the updated clas-
sification criteria. We also identified patients with other
autoimmune diseases including rheumatoid arthritis,
SLE, Sjögren’s syndrome, idiopathic inflammatory myo-
sitis, type I diabetes mellitus, and multiple sclerosis
using the catastrophic illness registry. The case defin-
ition of psoriasis was based on two recordings of
rheumatologist or dermatologist diagnosis.
Statistical analysis
The prevalence of SSc was calculated for individuals
with affected first-degree relatives and for the general
population. Any individual with a valid insurance regis-
tration in 2010 who met the case definition of SSc be-
tween 1 January 1996 and 31 December 2010 was
defined as a prevalent case. The number of individuals
in the 2010 general population in Taiwan was used as
the denominator for the prevalence of SSc. The recur-
rence risk for SSc was defined as the likelihood of having
a diagnosis of SSc in an individual with affected first-
degree relatives with a diagnosis of SSc. We calculated
recurrence risk for a specific type of relative (sibling and
offspring) of patients with SSc as the prevalence of SSc
in individuals with a specific type of affected relative
[13]. The adjusted prevalence ratio was used as a meas-
ure for relative risk (RR) for SSc [14], and was calculated
as the prevalence of SSc among individuals with affected
relatives divided by the prevalence of SSc in the general
population. The RR estimated in this study is equivalent
to the relative recurrence ratio (RRR) but for simplicity
we refer it as RR throughout. The marginal Cox propor-
tional hazard model with an equal follow-up time for all
subjects was used to estimate the RR and the 95 % confi-
dence interval (CI) [15]. We used the robust sandwich
estimator to calculate corrected CIs to account for pos-
sible case clustering within the family [16]. This ap-
proach has been applied and validated previously in
other diseases [17]. Covariates included age, gender, so-
cioeconomic factors (place of residence, occupation, and
income levels), and family size. A place of residence for
each individual was categorised according to the level of
urbanisation [18]. Occupations were classified into five
categories and income levels were categorised into sex-
specific income quintiles.
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Heritability was defined as the proportion of pheno-
typic variance that is attributable to genetic factors, and
familial transmission as the sum of heritability and the
proportion attributable to shared environmental factors;
both can be calculated using the polygenic liability
model [19–21]. The familial transmission in this study
was estimated as the function of the difference of normal
deviation of the threshold from the mean liability be-
tween individuals with affected siblings and the normal
population. The original model assumes zero common
environmental variance and, therefore, familial transmis-
sion equals heritability. However, we consider this as-
sumption not applicable in the case of SSc considering
known environmental factors that may predispose to the
disease and be shared among family members. In our
previous paper, we further used spouses as a control to
separate the shared environmental component and herit-
ability [11]. As SSc is predominantly a female disease
and its prevalence is low, it was not possible to identify
enough affected spouse pairs to produce reliable esti-
mates. Therefore, we only reported familial transmis-
sion. Next, we calculated the probability of a patient
with SSc without a family history according to the
formula based on a polygenic liability model devel-
oped by Yang et al. [22].
We further estimated the extent of familial co-
aggregation of other autoimmune diseases in affected
families. RRs and 95 % CIs for rheumatoid arthritis, SLE,
Sjögren’s syndrome, idiopathic inflammatory myositis,
type I diabetes mellitus, multiple sclerosis, and psoriasis
were estimated as the adjusted prevalence ratio of speci-
fied autoimmune diseases between individuals with a
first-degree relative with SSc and the general population.
We estimated the RR for other autoimmune diseases by
a marginal Cox proportional hazards regression model
with an equal follow-up time for all subjects. The RRs
were adjusted for age, sex, and family size, and consid-
ered case clustering within families by using the robust
sandwich estimate.
A two-sided p value ≤0.05 was considered statistically
significant. All analyses were performed using SAS v.9.3
(SAS institute, Cary, NC, USA).
Results
Among 23,658,577 individuals enrolled in the NHI data-
base in Taiwan in 2010, there were 1891 individuals
(1495 women; 396 men) with SSc, equivalent to a preva-
lence of 0.008 % (women, 0.013 %; men, 0.003 %). In the
general population of Taiwan in 2010, 3801 individuals
had at least one first-degree relative with SSc. The base-
line characteristics were shown in Table 1. Among
people with a family history of SSc, three people had SSc
which was equivalent to a prevalence of 0.08 %. Overall,
having an affected first-degree relative with SSc was
associated with an adjusted RR (95 % CI) of 13.23 (3.11–
56.33) for the disease. For risks for specific kinship, RRs
were 81.22 (11.40–578.72) for siblings and 9.17 (1.30–
65.86) for offspring of patients with SSc. Using a poly-
genic liability model, we estimated that the familial
transmission for SSc was 0.72. We estimated that 84.1 %
of patients with SSc were expected to be sporadic cases.
Table 2 presents adjusted RR (95 % CIs) for other
autoimmune diseases in individuals with affected first-
degree relatives compared to the general population.
The RR (95 % CI) in first-degree relatives of SSc patients
was 2.64 (1.46–4.75) for rheumatoid arthritis, 6.51
(4.05–10.46) for SLE, 2.77 (1.04–7.35) for Sjögren’s syn-
drome, 8.05 (2.03–31.92) for idiopathic inflammatory
myositis, and 1.52 (1.15–2.01) for psoriasis.
Discussion
This study investigated the risk of SSc in individuals
with affected first-degree relatives and estimated the fa-
milial transmission of SSc in a general population. We
Table 1 Baseline characteristics of individuals with affected
relatives with systemic sclerosis and the general population
Variables ≥1 Affected
relatives
General population P value
No. 3801 23,658,577
Male gender (n (%)) 2037 (53.59) 11,732,064 (49.59) <0.001
Age (years) (mean ± SD) 46.6 ± 16.2 37.5 ± 20.4 <0.001
Systemic sclerosis (n (%)) 3 (0.08) 1891 (0.008) <0.001
Place of residence (n (%))
Urban 2421 (63.69) 13,935,055 (58.90) <0.001
Suburban 991 (26.07) 6,581,657 (27.82)
Rural 267 (7.02) 2,186,647 (9.24)
Unknown 122 (3.21) 955,218 (4.04)
Income levels (n (%))
Quintile 1 594 (15.63) 4,077,139 (17.23) <0.001
Quintile 2 529 (13.92) 3,334,917 (14.10)
Quintile 3 881 (23.18) 6,296,926 (26.62)
Quintile 4 830 (21.84) 4,547,059 (19.22)
Quintile 5 847 (22.28) 4,437,878 (18.76)
Unknown 120 (3.16) 964,658 (4.08)
Occupation (n (%))
Dependents of the insured
individuals




195 (5.13) 984,451 (4.16)
Non-manual workers and
professionals
1426 (3752) 6,357,208 (26.87)
Manual workers 631 (16.60) 4,885,084 (20.65)
Other 364 (9.58) 2,222,500 (9.39)
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found that the prevalence of SSc in relatives of patients
with the disease is significantly higher than the general
population and that the familial transmission of SSc was
0.72. Despite this, most cases of SSc are expected to be
sporadic under the polygenic liability model. Further-
more, individuals with an affected first-degree relative
with the disease also have a higher prevalence of other
autoimmune diseases. These estimates are valuable for
clinical counselling, and also for the preparation of fu-
ture genetic studies to determine candidate susceptibility
genes.
Formal evidence for familial aggregation and the mag-
nitude of any familial or genetic contribution for SSc is
rarely reported [6, 7, 23]. Englert et al. identified 710
Australian families with SSc and reported a prevalence
of 1.4 % and a RR of 11 in people with affected family
members [6]. Another study from the US reported a risk
of 1.6 % in those with an affected first-degree relative
and the RR was 13 [7]. The risk of SSc in an individual
with an affected first-degree relative was estimated to be
1.1 %, which was 3.5-fold higher than the controls [23].
Another Canadian study reported that 2.8 % of indi-
viduals with a positive family history of SSc had the
disease [24]. These studies in general indicate a high
familial absolute and relative risk for SSc. However,
the estimates vary over a wide range, probably due to
variable study design, case ascertainment, and family
member recruitment.
Estimates from both studies are similar to our study
and indicate a high familiarity of SSc. Concordance of
SSc in twins has been reported previously [25, 26]. In
addition, monozygotic twins discordant for SSc were
found to have a similar fibroblast gene expression pat-
tern, suggesting a strong genetic predisposition to SSc at
the molecular level in skin fibroblasts [27]. Interestingly,
a small twin study comprising 24 monozygotic and 18
dizygotic twin pairs found a similar concordance rate for
SSc between monozygotic (4.2 %) and dizygotic twin
pairs (5.6 %). However, the concordance for a positive
test for antinuclear antibody was very high (90 % in
monozygotic and 40 % in dizygotic twins) [28]. In
addition to twins, two reports have indicated familial
forms of both diffuse cutaneous SSc [29, 30] and lim-
ited cutaneous SSc [31]. A positive family history of
SSc is thought to represent the largest risk factor for
this disease with a familial RR of 15 [7]. Using the
Utah Population Database, the familial RR for SSc
was approximately 2 to 3 in first- to third-degree rel-
atives, but there is no apparent association between
the magnitude of RR and genetic relatedness [32].
Heritability of SSc has not been assessed before; how-
ever, a twin study comprising 702 monozygotic and
727 dizygotic twin pairs reported a significant herit-
ability (0.53) for Raynaud’s phenomenon [33].
Our study provides several lines of evidence support-
ing the importance of familial factors, including both
genes and environment, in the susceptibility of SSc.
Firstly, the prevalence of SSc was significantly higher in
first-degree relatives of SSc patients than in the general
population, in addition to a high familial RR. Secondly,
using the polygenic liability model, we estimated that
72 % of phenotypic variance can be explained by familial
factors (familial transmission). Despite this apparent fa-
milial factor in the susceptibility of SSc, most patients
are expected to be sporadic rather than familial under
the polygenic liability model as with many common
complex diseases [11, 22]. For example, 78–84 % of pa-
tients with rheumatoid arthritis, SLE [22], and Sjögren’s
syndrome [11] are expected to be sporadic cases de-
pending on the parameters used [22].
In addition to SSc, other autoimmune diseases are
more common in family members of patients with the
disease, which suggest that some autoimmune diseases
share part of the pathogenesis of SSc. Previous studies
have documented that autoimmune diseases often co-
aggregate within families. Several studies also found an
increased risk of other autoimmune disease in family
members of SSc patients [9–11, 23, 24, 34, 35]. A
Table 2 Relative risks of systemic sclerosis and other autoimmune diseases for individuals with affected first-degree relatives
Autoimmune diseases With affected relatives General population Relative risk (95 % CI)a
No. of cases Prevalence (%) No. of cases Prevalence (%)
Systemic sclerosis 3 0.08 1891 0.008 13.23 (3.11–56.33)
Rheumatoid arthritis 11 0.29 37,482 0.16 2.64 (1.46–4.75)
Systemic lupus erythematosus 20 0.53 18,915 0.08 6.51 (4.05–10.46)
Sjögren’s syndrome 4 0.11 12,754 0.05 2.77 (1.04–7.35)
Idiopathic inflammatory myositis 2 0.05 1808 0.01 8.05 (2.03–31.92)
Type I diabetes mellitus 5 0.13 10,281 0.04 2.51 (0.90–7.07)
Multiple sclerosis 1 0.03 1252 0.01 5.16 (0.73–3665)
Psoriasis 47 1.24 196,333 0.83 1.52 (1.15–2.01)
a Adjusted for age, gender, place of residence, quintiles of income levels, occupations, and family size
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relatively large study investigating 4612 first-degree rela-
tives of 1071 SSc probands found that the most preva-
lent autoimmune diseases among first-degree relatives of
SSc patients were hypothyroidism, rheumatoid arthritis,
hyperthyroidism, and SLE [34]. Collectively, our results
provide useful information when counselling patients
and their family members in which circumstances and
details of genetic parameters related to SSc should be
given and explained in full. An unselective screening for
SSc and other autoimmune diseases in all asymptomatic
family members of patients with SSc is not recom-
mended given a low absolute risk of these conditions.
On the contrary, a positive family history is an important
hint for those suspected of having an autoimmune dis-
ease. However, further study should be undertaken to
test the utility of family history as a tool to identify at-
risk individuals.
Limitations and strengths
There are limitations to the present study. Firstly, the
classification of cases was based on the diagnosis re-
corded in the registry of patients with catastrophic
illnesses or based on records in primary care. Neverthe-
less, issuance of a catastrophic illness certificate requires
strong medical evidence for a diagnosis of SSc that is
agreed by an expert panel, and applications for these
certificates are submitted almost exclusively by rheuma-
tologists. Therefore, any misclassification is unlikely to
affect our conclusions. However, some patients with
milder disease may not have applied for the certificate
and this might affect our results. Secondly, we are not
able to differentiate different forms of SSc. Thirdly, our
model cannot effectively separate contributions from
genetic and shared environmental factors. Finally, whether
these results apply to different populations and settings
outside of Taiwan requires further study.
Conclusions
This nationwide study confirms that, in Taiwan, SSc
clusters within families and familial factors contribute to a
large proportion of the susceptibility to the disease. Rela-
tives of patients with SSc tend to have an increased risk of
other autoimmune diseases. These findings may also be
useful in counselling families with patients with SSc.
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